 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
| 123456789» |
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela, Takecab (vonoprazan) / Takeda, Phathom Pharma
Retrospective data, Review, Journal: P-CAB versus PPI in the eradication of Helicobacter pylori: a systematic review and network meta-analysis. (Pubmed Central) - May 16, 2024
In the eradication treatment of Hp, the efficacy and safety of vonoprazan-based regimens are generally better than those of PPI-based regimens. Among them, the V-Tri-2w regimen has the highest eradication rate and may be the preferred choice for Hp eradication.
- | Takecab (vonoprazan) / Takeda, Phathom Pharma
Journal: VONOPRAZAN IS EFFICACIOUS FOR TREATMENT OF HEARTBURN IN NON-EROSIVE REFLUX DISEASE: A RANDOMIZED TRIAL. (Pubmed Central) - May 16, 2024
P3
The two vonoprazan doses (10 and 20mg) were similar in efficacy. (ClinicalTrials.gov:NCT05195528).
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela
P1 data, PK/PD data, Journal: Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial. (Pubmed Central) - May 11, 2024
The plasma exposure of tegoprazan, M1, 14-hydroxyclarithromycin and bismuth was increased after the coadministration of tegoprazan, clarithromycin, amoxicillin and bismuth. The coadministration exhibited favorable safety and tolerability.
- || Fexuclue (fexuprazan) / Daewoong Pharma
Clinical, PK/PD data, Journal: Pharmacokinetic interactions between fexuprazan, a potassium-competitive acid blocker, and nonsteroidal anti-inflammatory drugs in healthy males. (Pubmed Central) - May 3, 2024
There were no significant changes in the systemic exposure of fexuprazan by celecoxib and meloxicam. Fexuprazan and NSAIDs did not show clinically meaningful PK interactions.
- | Journal: Effect of Laryngopharyngeal Reflux and Potassium-Competitive Acid Blocker (P-CAB) on the Microbiological Comprise of the Laryngopharynx. (Pubmed Central) - Apr 29, 2024
Fexuprazan and NSAIDs did not show clinically meaningful PK interactions. Laryngopharyngeal microbial communities changed after laryngopharyngeal reflux and were modified further after P-CAB treatment, which provides a potential diagnostic value for LPRD, especially when combined with clinical indices.
- || Review, Journal: Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and Helicobacter pylori. (Pubmed Central) - Apr 24, 2024
These results have translated in clinical studies to similar and, in some cases, improved outcomes relative to PPIs in these disease states. This review summarizes current knowledge on the physiology of acid secretion, pathophysiology and management of GERD and H. pylori, and key characteristics and clinical trial data for PPIs and PCABs.
- | Takecab (vonoprazan) / Takeda, Phathom Pharma
Journal: Long-term follow-up of patients developing gastric mucosal lesions after initiating the potassium-competitive acid blocker vonoprazan. (Pubmed Central) - Apr 18, 2024
This review summarizes current knowledge on the physiology of acid secretion, pathophysiology and management of GERD and H. pylori, and key characteristics and clinical trial data for PPIs and PCABs. No abstract available
- | Journal: Long-term course of untreated asymptomatic esophageal eosinophilia and minimally symptomatic eosinophilic esophagitis. (Pubmed Central) - Apr 17, 2024
Instead, the localized type may spontaneously improve, implying a different pathogenesis in the presence of the diffuse type. Further studies should clarify the long-term prognosis.
- | Journal: Long-term Outcome of Asymptomatic Esophageal Eosinophilia. (Pubmed Central) - Apr 16, 2024
Symptoms developed in cases where endoscopic and pathologic findings remained unchanged or worsened during follow-up. : Some patients with aEE had improved findings without treatment, whereas others developed symptoms, emphasizing the importance of long-term monitoring and individualized treatment decisions.
- || Takecab (vonoprazan) / Takeda, Phathom Pharma
Clinical, Journal: Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori: Current perspectives and implications. (Pubmed Central) - Apr 14, 2024
Nonetheless, S. boulardii comes in various formulations and dosages, warranting further exploration into the optimal dosage for supplementation in rescue therapy. Additionally, larger, randomized, double-blinded controlled trials are warranted to confirm these promising results.
- || Clinical, Retrospective data, Review, Journal: Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis. (Pubmed Central) - Apr 9, 2024
VPZ-based triple therapy outperformed conventional PPI-based triple therapy in eradicating H. pylori, positioning it as a highly effective first-line regimen. Additionally, TPZ-based triple therapy was non-inferior to classical PPI triple therapy.
- ||| Fexuclue (fexuprazan) / Daewoong Pharma
Clinical, P3 data, Journal: The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study. (Pubmed Central) - Apr 4, 2024
P3
The incidence of TEAEs was similar between fexuprazan and esomeprazole. Trial registration number NCT05813561.
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela
Clinical, Journal: Comparison of the efficacy between the dual therapy of tegoprazan and the quadruple therapy of tegoprazan: A randomized, controlled, multicenter study. (Pubmed Central) - Apr 1, 2024
The TA dual therapy successfully eradicated H. pylori with a high eradication rate and a low incidence of adverse reactions. Therefore, this treatment is recommended as an alternative course for patients newly diagnosed with H. pylori infection.
- | Takecab (vonoprazan) / Takeda, Phathom Pharma
Journal: Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor: A Pilot Study on Comparable Efficacy in the Treatment of Gastroesophageal Reflux-Related Cough. (Pubmed Central) - Mar 26, 2024
The long-term efficacy of P-CABs on GERC may be worth further exploration. Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2200067089.
- || Takecab (vonoprazan) / Takeda, Phathom Pharma
Retrospective data, Review, Journal: A systematic review with meta-analysis: Efficacy and safety of potassium-competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis. (Pubmed Central) - Mar 25, 2024
Vonoprazan 10 and 20?mg were superior to lansoprazole 15?mg in the maintenance of the healing of EE. Any TEAEs were greater with vonoprazan 20?mg.
- || Review, Journal: Anti-reflux mucosectomy (ARMS) for refractory gastroesophageal reflux disease. (Pubmed Central) - Mar 23, 2024
Of these, antireflux mucosectomy (ARMS) is an effective and safe therapy for refractory GERD. This review provides an updated summary of antireflux mucosectomy.
- K-CAB Tab (tegoprazan) / RaQualia, Sebela
Potassium-competitive acid blocker use is associated with a lower risk of renal function deterioration compared to proton pump inhibitor use (T6) - Mar 23, 2024 - Abstract #ERAEDTA2024ERA_EDTA_2107;
Given the renal safety concerns of PPIs, using P-CAB could be a relatively safer strategy for preserving kidney function in patients who need long-term gastric acid suppression. Further studies with a larger cohort incorporating other P-CABs are required to validate this finding.
- | K-CAB Tab (tegoprazan) / RaQualia, Sebela
Journal: The Effect of Tegoprazan on the Treatment of Endoscopic Resection-Induced Artificial Ulcers: A Multicenter, Randomized, Active-Controlled Study. (Pubmed Central) - Mar 15, 2024
Other adverse events were negligible in both groups. : Tegoprazan showed similar effects on post-ESD artificial ulcer healing in comparison with esomeprazole.
- Jaqbo (zastaprazan) / Jeil
RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZASTAPRAZAN COMPARED WITH ESOMEPRAZOLE IN EROSIVE ESOPHAGITIS [ZASTAPRAN EROSIVE REFLUX OESOPHAGITIS-1 STUDY (ZERO-1)] (Ballroom A - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_8309;
P2
The healing rate at week 4 appears to be higher for zastaprazan than esomeprazole at week 4. These findings suggest that zastaprazan would be a promising alternative to proton pump inhibitors for the treatment of erosive esophagitis.
- K-CAB Tab (tegoprazan) / RaQualia, Sebela
CLINICAL OUTCOMES OF TEGOPRAZAN OR PPI COMBINATION THERAPY IN PATIENTS TAKING ANTIPLATELET AGENTS AFTER PERCUTANEOUS CORONARY INTERVENTION (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7114;
The two groups did not differ significantly in the overall rates of GI and CV adverse events. CONCLUSIONS Tegoprazan was non-inferior to PPIs in terms of GI and CV adverse events in IHD patients receiving antiplatelet agents after PCI.
- Takecab (vonoprazan) / Takeda, Phathom Pharma
VONOPRAZAN FOR THE TREATMENT OF HEARTBURN IN NON-EROSIVE REFLUX DISEASE: A RANDOMIZED TRIAL (146AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6208;
Treatment effect persisted after the initial 4-week placebo-controlled period throughout the 20-week extension period. The two vonoprazan doses (10 and 20mg) were similar in efficacy.
- K-CAB Tab (tegoprazan) / RaQualia, Sebela, Fexuclue (fexuprazan) / Daewoong Pharma, Takecab (vonoprazan) / Takeda, Phathom Pharma
IDENTIFICATION OF RD1305, A NEXT GENERATION POTASSIUM-COMPETITIVE ACID BLOCKER (P-CAB) FOR GASTROESOPHAGEAL REFLUX DISEASES (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5080;
In solubility assay, RD1305 expressed improving aqueous solubility (pH 6.8) 256-fold higher than existing P-CAB drugs. Conclusion Consequently, RD1305 is next generation P-CAB that improves the efficacy and physio-chemical properties of existing P-CABs.
- Takecab (vonoprazan) / Takeda, Phathom Pharma
THE EFFICACY OF VONOPRAZAN VS. LANSOPRAZOLE IN TREATING EROSIVE ESOPHAGITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5072;
In other words, Vonoprazan is overall non-inferior to Lansoprazole in achieving the healing phase determined by endoscopy. It would be interesting to pay attention to further randomized controlled trials looking at the use of Vonoprazan in patients who are intolerant to PPIs in treating erosive esophagitis or severe gastroesophageal reflux disease.
- THE EFFICACY AND SAFETY OF POTASSIUM COMPETITIVE ACID BLOCKERS (PCABS) VS. PROTON PUMP INHIBITORS (PPIS) IN EROSIVE ESOPHAGITIS, AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5071;
Additionally, more patients using PCABs were free of heartburn symptoms than patients using PPIs. PCABs also had a similar rate of adverse events compared to PPIs showing their safety with short term use.
- Takecab (vonoprazan) / Takeda, Phathom Pharma
FINAL SAFETY AND EFFECTIVENESS RESULTS OF VONOPRAZAN IN CHINESE REFLUX ESOPHAGITIS PATIENTS: A MULTI-CENTER PROSPECTIVE REAL-WORLD STUDY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5065;
P=N/A
Of patients who presented with heartburn, night-time heartburn, regurgitation, or night-time regurgitation at enrollment, complete symptom relief was observed in 32.3%, 43.8%, 27.0% and 40.5% patients, respectively during first week of treatment and in 58.0%, 68.9%, 50.8% and 63.0% patients, respectively first two weeks after treatment (Table 1). Conclusion Vonoprazan showed favorable safety profile and effectiveness in Chinese RE patients in real-world settings.
- Takecab (vonoprazan) / Takeda, Phathom Pharma
FINAL SAFETY AND EFFECTIVENESS OF VONOPRAZAN IN ELDERLY CHINESE REFLUX ESOPHAGITIS PATIENTS: A MULTI-CENTER PROSPECTIVE REAL-WORLD STUDY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5064;
P=N/A
Of patients presenting with heartburn, night-time heartburn, regurgitation, or night-time regurgitation at enrollment, the proportion of patients who had complete symptom relief for first week of treatment were 30.4%, 40.0%, 28.1%, and 41.5%, respectively and for first 2 weeks of treatment were 60.6%, 67.2%, 52.6%, and 62.8%, respectively (Table 2). Conclusion This subgroup analysis results demonstrated that vonoprazan is well-tolerated and effectively relieved symptoms in elderly Chinese RE patients in real-world setting.
- K-CAB Tab (tegoprazan) / RaQualia, Sebela, Takecab (vonoprazan) / Takeda, Phathom Pharma
COMPARISON OF LONG-TERM EFFECTS OF P-CAB AND PPI ON GASTRIC EMPTYING RATE, SERUM GASTRIN, AND SMALL INTESTINAL MICROBIOMES IN RATS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5061;
No significant differences were observed between PPIs and P-CABs in delayed gastric emptying, hypergastrinemia, and small intestinal dysbiosis after prolonged administration. These findings suggest that despite P-CABs exerting a more potent gastric acid inhibitory effect than PPIs, the adverse effects associated with long-term gastric acid inhibition are likely to be similar between the two drug classes.
- Fexuclue (fexuprazan) / Daewoong Pharma
ANALYSIS OF MAJOR SYMPTOM RELIEF: A COMPARISON BETWEEN FEXUPRAZAN AND PROTON PUMP INHIBITOR FOR FULL DAY AND NIGHTTIME HEARTBURN/ACID REFLUX IN PATIENTS WITH EROSIVE ESOPHAGITIS OVER THE 8-WEEK TREATMENT PERIOD. (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5060;
P3
However, additional analysis demonstrated that the proportion of symptom-free days of major symptoms in the first 7 days, 4 weeks, and 8 weeks of treatment were numerically higher in Fexuprazan than Esomeprazole, especially at nighttime. Furthermore, Fexuprazan demonstrated a higher relief in moderate-to-severe heartburn symptoms, both better and sooner than Esomeprazole, particularly by day 1-3, 1-4 of the treatment.
- Takecab (vonoprazan) / Takeda, Phathom Pharma
DIFFERENCES BETWEEN PATIENTS WITH HEARTBURN REFRACTORY TO VONOPRAZAN AND THOSE REFRACTORY TO PROTON PUMP INHIBITORS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5036;
Furthermore, Fexuprazan demonstrated a higher relief in moderate-to-severe heartburn symptoms, both better and sooner than Esomeprazole, particularly by day 1-3, 1-4 of the treatment. Patients with vonoprazan-refractory NERD were more symptomatic than those with PPI-refractory NERD, and those symptoms includes not only GERD symptoms but also functional dyspepsia and irritable bowel syndrome symptoms.
- Takecab (vonoprazan) / Takeda, Phathom Pharma
CHARACTERISTICS OF ENDOSCOPIC FINDINGS OF PPI/P-CAB-RELATED GASTROPATHY FOR PATIENTS USING EACH ANTACID (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4980;
It was suggested that the prevalence of each endoscopic finding in PPI/P-CAB-related gastropathy may have different depending on each antacid. Further accumulation regarding P-CAB-related gastropathy is required in the future.
- K-CAB Tab (tegoprazan) / RaQualia, Sebela
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY PHASE III CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF BISMUTH QUADRUPLE THERAPY CONTAINING TEGOPRAZAN COMPARED TO ESOMEPRAZOLE IN ERADICATING HELICOBACTER PYLORI IN CHINA (140AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4464;
This is the first phase III study to show that P-CAB-containing bismuth quadruple therapy was superior to PPI-containing bismuth quadruple therapy in overall study population. The bismuth quadruple therapy containing tegoprazan 50mg twice daily for 14 days was safe and well tolerated for treating H. pylori infection in Chinese patients.
- Takecab (vonoprazan) / Takeda, Phathom Pharma
EFFICACY OF VONOPRAZAN 10 MG AND 20 MG FOR PATIENTS WITH PROTON PUMP INHIBITORS (PPI)-REFRACTORY FUNCTIONAL DYSPEPSIA (FD): A DOUBLE-BLINDED, RANDOMIZED STUDY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3151;
Vonoprazan demonstrated significant effects in the alleviation of symptoms in PPI-refractory FD patients. There was no statistically significant difference in symptom alleviation between the 10 mg and 20 mg doses of vonoprazan.
- Fexuclue (fexuprazan) / Daewoong Pharma
FEXUPRAZAN PROTECTS AGAINST HCL-INDUCED INFLAMMATION AND DAMAGE BY INHIBITING THE NLRP1/CASPASE-1/GASDERMIN D PYROPTOTIC PATHWAY IN THE ESOPHAGUS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_2971;
Esomeprazole, a representative PPI, and three currently marketed P-CABs (vonoprazan, tegoprazan, and fexuprazan) were pretreated. Fexuprazan inhibits inflammation and pyroptosis of esophageal cells caused by stomach acid, so it is presumed to have additional benefits in gastroesophageal reflux disease in addition to suppressing gastric acid secretion.
- Fexuclue (fexuprazan) / Daewoong Pharma
FEXUPRAZAN, A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER, AMELIORATES NSAID-INDUCED SMALL INTESTINAL MUCOSAL INJURY BY RESTORING THE EPITHELIAL BARRIER INTEGRITY IN MICE. (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_2913;
Fexuprazan emerges as a potential therapeutic alternative to PPIs, demonstrating efficacy in ameliorating indomethacin-induced epithelial injury by restoring the integrity of intestinal epithelial cell junctions. Fexuprazan may serve as a promising option against NSAID-induced enteropathy.
- THE SAME RESULT AS GASTRIC POLYPECTOMY ARE ACHIEVED SIMPLY BY REDUCING, IF NOT DISCONTINUING, THE SUPPRESSION OF GASTRIC ACID SECRETION. (ePosters - DDW Online Platform) - Mar 14, 2024 - Abstract #DDW2024DDW_1451;
(Conclusions) This study demonstrated that a relative reduction in gastric acid secretion suppression, which recognized as non-endoscopic polypectomy, provided a therapeutic effect for GFHP equivalent to that of endoscopic treatment. Therefore, it would be very significant to first try to see if reducing gastric acid secretion suppression therapy if not discontinuation would result in GFHP reduction.
- Fexuclue (fexuprazan) / Daewoong Pharma, Takecab (vonoprazan) / Takeda, Phathom Pharma
EFFICACY OF NOVEL POTASSIUM-COMPETITIVE ACID BLOCKERS, VONOPRAZAN AND FEXUPRAZAN, VERSUS CONVENTIONAL PROTON PUMP INHIBITOR-BASED TRIPLE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI, A RETROSPECTIVE COHORT STUDY IN A PHILIPPINE TERTIARY HOSPITAL (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1000;
This study concludes that Vonoprazan and Fexuprazan-based regimens exhibit non-inferiority to the standard PPI-based regimen for H. pylori eradication. This suggests a potential role for P-CAB medications in H. pylori treatment in the Philippine population.
- TREATMENT OF HELICOBACTER PYLORI WITH POTASSIUM COMPETITIVE ACID BLOCKERS: A SYSTEMATIC REVIEW AND META-ANALYSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_993;
Vonoprazan-based triple therapy outperformed conventional PPI-based triple therapy in eradicating H. pylori, positioning it as a highly effective first-line regimen. Additionally, Tegoprazan-based triple therapy wass non-inferior to classical PPI triple therapy.
- Fexuclue (fexuprazan) / Daewoong Pharma
ANTI-INFLAMMATORY PROPERTIES OF FEXUPRAZAN VIA NF-?B INHIBITION AGAINST HELICOBACTER PYLORI CAGA-INDUCED INFLAMMATION (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_991;
and MAPK signaling pathways, which led to the significant reduction of pro-inflammatory cytokines. These results suggest that fexuprazan has a potential for anti-inflammatory strong protective effects on gastric mucosa in addition to its major role as an acid suppressant.
- Takecab (vonoprazan) / Takeda, Phathom Pharma
SEVEN-DAY VONOPRAZAN-BASED TRIPLE THERAPY AS FIRST-LINE HELICOBACTER PYLORI TREATMENT IN COMPARISON WITH EXTENDED SEQUENTIAL THERAPY: A RANDOMIZED CONTROLLED TRIAL (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_988;
Compliance was higher in the VAC-7 group, with 94% taking all the pills correctly. Conclusions Our findings supported the use of seven-day vonoprazan triple therapy with high-dose amoxicillin as the standard first-line treatment for Helicobacter pylori infection.
- Takecab (vonoprazan) / Takeda, Phathom Pharma
BOTH 14-DAY VONOPRAZAN TRIPLE THERAPY AND 14-DAY RABEPRAZOLE REVERSE HYBRID THERAPY ARE SUPERIOR TO 14-DAY VONOPRAZAN HIGH-DOSE DUAL THERAPY FOR THE FIRST-LINE ANTI-H. PYLORI TREATMENT IN POPULATION WITH HIGH RATES OF ANTIBIOTIC RESISTANCE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_978;
The proportions of resistant strains to clarithromycin, amoxicillin, and metronidazole in the study population were 17.4%, 0.6%, and 28.5%, respectively. The interim report data suggest that eradication rates of 14-day vonoprazan triple therapy and 14-day rabeprazole reverse hybrid therapy are higher than that of 14-day vonoprazan high-dose dual therapy for the first-line treatment of H. pylori infection in populations with high rates of antibiotic resistance.
- Takecab (vonoprazan) / Takeda, Phathom Pharma
COMPARATIVE EFFICACY OF VONOPRAZAN WITH PROTON PUMP INHIBITORS AND OTHER POTASSIUM-COMPETITIVE ACID BLOCKERS FOR REFLUX ESOPHAGITIS: A NETWORK META-ANALYSIS (ePosters - DDW Online Platform) - Mar 14, 2024 - Abstract #DDW2024DDW_529;
Randomized controlled trials of (1) endoscopy-confirmed RE patients ?18 years, (2) receiving at least 2 of these intervention arms: vonoprazan, tegoprazan, kenoprazan, fexuprazan, linaprazan glurate and/or any oral PPIs, (3) reporting at least 1 clinical outcomes of healing rate at 4 weeks for vonoprazan, and 8 weeks for PPIs and other P-CABs and (4) those including >20 patients per group were considered...Specifically, ORs (95% CrI) of PPIs and other P-CABs versus vonoprazan were as follows: fexuprazan 40mg:2.0 (0.056,80.0), keverprazan 20mg:3.6 (0.96,15.0), tegoprazan 50mg:3.4 (0.76,17.0), esomeprazole 20mg:1.7 (0.69,4.1), esomeprazole 40mg:1.8 (0.94,3.4), ilaprazole 10mg:2.1 (0.91,4.8), lansoprazole 30mg:1.4 (0.76,2.4), omeprazole 20mg:1.2 (0.63,2.4), omeprazole 40mg:1.3 (0.53,3.1), pantoprazole 40mg:1.4 (0.70,2.8), and rabeprazole 20mg:1.0 (0.42, 2.3) (Figure 1)...Conclusion This is the first study showing similar efficacy of 4-week vonoprazan course to 8-week PPI course and other P-CABs in healing RE. These results may be helpful to inform clinical practice.
- | Takecab (vonoprazan) / Takeda, Phathom Pharma
Journal: Potassium-competitive acid blockers and acid-related disorders. (Pubmed Central) - Mar 14, 2024
The PCAB vonoprazan is a newly FDA approved treatment option for erosive esophagitis. Its possible role in PPI-resistant GERD and nonerosive reflux disease warrants further investigation.
- | Takecab (vonoprazan) / Takeda, Phathom Pharma
Journal: Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis. (Pubmed Central) - Mar 12, 2024
In treatment-naive patients with H pylori infection, both the 14-day VA and VBQT regimens demonstrated comparable efficacy, with excellent eradication rates. Moreover, due to reduced antibiotic usage, lower rate of AEs, and lower costs, VA dual therapy should be prioritized.
- | linaprazan glurate (X842) / Cinclus Pharma
Preclinical, Journal: Absorption, distribution, metabolism and excretion of linaprazan glurate in rats. (Pubmed Central) - Mar 12, 2024
Based on the structures, linaprazan glurate was mainly hydrolyzed into linaprazan, followed by a series of oxidation, dehydrogenation, and glucuronidation in rats. Besides, CES2 is the main metabolic enzyme involved in the hydrolysis of linaprazan glurate to linaprazan.
- || Takecab (vonoprazan) / Takeda, Phathom Pharma
Clinical, Journal: Effects of 1-kestose on microbiome changes caused by vonoprazan: a randomized, double-blind, placebo-controlled pilot study. (Pubmed Central) - Mar 5, 2024
The potassium-competitive acid blocker caused dysbiosis in the placebo group; this effect was prevented by 1-kestose. Thus, 1-kestose may be useful in dysbiosis treatment.
- || Revanex (revaprazan) / Yuhan Corp, Takecab (vonoprazan) / Takeda, Phathom Pharma
PK/PD data, Journal: Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling. (Pubmed Central) - Mar 4, 2024
This platform enables researchers to align the PK profile of a drug with desired PD effects at the early drug discovery stage. Case studies are presented to assess and compare five potassium-competitive acid blocker (P-CAB) compounds, after calibration and verification using vonoprazan and revaprazan.
- || Takecab (vonoprazan) / Takeda, Phathom Pharma
Review, Journal: Potassium-competitive acid blocker-associated gastric mucosal lesions. (Pubmed Central) - Feb 29, 2024
Since the introduction of vonoprazan, a potassium-competitive acid blocker (P-CAB), it has been demonstrated to reversibly inhibit gastric acid secretion by engaging in potassium-competitive ionic binding to H+/K+-ATPase...This review highlights the evident differences in the mechanism of action and potency of acid inhibition between P-CABs and PPIs, notably contributing to differences in the formation and frequency of associated gastropathies. It emphasizes the necessity to distinguish between P-CAB-related and PPI-related gastropathies in the clinical setting.
- || Retrospective data, Review, Journal: Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect. (Pubmed Central) - Feb 19, 2024
Overall, in terms of nocturnal acid-inhibitory effect, vonoprazan and tegoprazan had an advantage against other regimens including H2RAs, isomer PPIs, traditional PPIs, AHB, and new PPIs. Even in some subgroups, such as language classification (English), types of study design (crossover-RCT), age (?40?years), BMI (18.5-24.9?kg/m2 ), continent (Asia and North America), disease status (health), the duration of therapy (2?weeks), and time of administration (at daytime or at night-time), the nocturnal acid-inhibitory effect of vonoprazan or tegoprazan were better than most regimens, even AHB and new PPIs.
- || Takecab (vonoprazan) / Takeda, Phathom Pharma
Retrospective data, Review, Journal: Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials. (Pubmed Central) - Feb 14, 2024
Even in some subgroups, such as language classification (English), types of study design (crossover-RCT), age (?40?years), BMI (18.5-24.9?kg/m2 ), continent (Asia and North America), disease status (health), the duration of therapy (2?weeks), and time of administration (at daytime or at night-time), the nocturnal acid-inhibitory effect of vonoprazan or tegoprazan were better than most regimens, even AHB and new PPIs. Vonoprazan 20
- || K-CAB Tab (tegoprazan) / RaQualia, Sebela, Takecab (vonoprazan) / Takeda, Phathom Pharma
Retrospective data, Review, Journal: Comparative efficacy of P-CABs versus proton pump inhibitors for Grade C/D esophagitis: A systematic review and network meta-analysis. (Pubmed Central) - Feb 12, 2024
Vonoprazan 20 Vonoprazan has considerable efficacy in initial and maintained healing of grade C/D esophagitis compared with PPIs, with moderate short-term and long-term safety.